文献速递认知障碍与痴呆

阿尔茨海默病患者纵向血浆神经丝轻链与神经变性的关联

Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
PubMed 文献 · JAMA Neurol · 2019-01-01

本研究基于阿尔茨海默病神经影像学倡议(ADNI)队列1583名参与者,分析纵向血浆神经丝轻链(NfL)水平与临床诊断、脑脊液生物标志物、影像及认知指标的关系。结果显示血浆NfL在轻度认知障碍和AD痴呆患者中升高,且纵向增加与脑脊液Aβ42降低、tau升高、海马萎缩、皮层变薄、脑室扩大、FDG-PET低摄取及认知下降相关,提示其可作为无创监测神经变性的生物标志物。

要点

  • 血浆NfL在AD痴呆患者中升高最明显,且随疾病进展纵向增加。
  • 血浆NfL纵向增加与脑脊液Aβ42降低、总tau及磷酸化tau升高相关。
  • 血浆NfL增加与海马萎缩、皮层变薄、脑室扩大、FDG-PET低摄取及认知下降相关。

核心结论

  • 血浆NfL可作为与AD神经变性相关的无创生物标志物,并可能用于监测疾病修饰药物试验中的效果。

研究设计与样本

  • 北美多中心队列研究,纳入ADNI研究中1583名有NfL测量的个体,收集长达11年的年度血浆样本,于2018年分析。

主要发现

  • 基线NfL均值:认知正常32.1 ng/L,轻度认知障碍37.9 ng/L,AD痴呆45.9 ng/L(P < .001)。
  • NfL纵向增加与基线低Aβ42(P = .001)、高总tau(P = .02)、高磷酸化tau(P = .02)相关。
  • NfL纵向增加与海马体积小(P < .001)、皮层薄(P = .009)、脑室大(P = .002)、FDG-PET低摄取(P = .01)及全局认知差(P < .001)相关。
  • ATN系统中,基线NfL在A-T+N+、A+T-N+、A+T+N+组升高(均P < .001);NfL增长率在A-T+N-(P = .009)、A-T+N+(P = .02)、A+T-N+(P = .04)、A+T+N+(P = .002)组加快。
  • NfL增长越快与脑脊液神经元损伤标志物增长越快、萎缩和代谢减低速率越快、全局认知恶化越快相关(轻度认知障碍患者所有P < .05)。

关键数值与推荐

  • 基线NfL均值认知正常32.1 ng/L、轻度认知障碍37.9 ng/L、AD痴呆45.9 ng/L(P < .001)。
  • NfL纵向增加与低Aβ42(P = .001)、高总tau(P = .02)、高磷酸化tau(P = .02)相关。
  • NfL纵向增加与海马体积小(P < .001)、皮层薄(P = .009)、脑室大(P = .002)、FDG-PET低摄取(P = .01)、全局认知差(P < .001)相关。
  • ATN分组基线NfL升高:A-T+N+、A+T-N+、A+T+N+(均P < .001);NfL增长率加快:A-T+N-(P = .009)、A-T+N+(P = .02)、A+T-N+(P = .04)、A+T+N+(P = .002)。

临床怎么用

  • 血浆NfL可作为无创工具辅助监测AD患者的神经变性进程。
  • 在临床试验中,血浆NfL或可用于监测疾病修饰药物的生物学效应。
  • 解读NfL变化时需结合临床诊断、脑脊液生物标志物、影像及认知评估综合判断。

局限性

  • 研究为观察性队列,不能确立因果关系。
  • NfL纵向变化与脑脊液、影像及认知的关联在认知正常对照和AD痴呆患者中略有不同。
  • 血浆NfL并非AD特异性标志物,可能受其他神经疾病影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Plasma neurofilament light (NfL) has been suggested as a noninvasive biomarker to monitor neurodegeneration in Alzheimer disease (AD), but studies are lacking. OBJECTIVE: To examine whether longitudinal plasma NfL levels are associated with other hallmarks of AD. DESIGN, SETTING, AND PARTICIPANTS: This North American cohort study used data from 1583 individuals in the multicenter Alzheimer's Disease Neuroimaging Initiative study from September 7, 2005, through June 16, 2016. Patients were eligible for inclusion if they had NfL measurements. Annual plasma NfL samples were collected for up to 11 years and were analyzed in 2018. EXPOSURES: Clinical diagnosis, Aβ and tau cerebrospinal fluid (CSF) biomarkers, imaging measures (magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography), and tests on cognitive scores. MAIN OUTCOMES AND MEASURES: The primary outcome was the association between baseline exposures (diagnosis, CSF biomarkers, imaging measures, and cognition) and longitudinal plasma NfL levels, analyzed by an ultrasensitive assay. The secondary outcomes were the associations between a multimodal classification scheme with Aβ, tau, and neurodegeneration (ie, the ATN system) and plasma NfL levels and between longitudinal changes in plasma NfL levels and changes in the other measures. RESULTS: Of the included 1583 participants, 716 (45.2%) were women, and the mean (SD) age was 72.9 (7.1) years; 401 had no cognitive impairment, 855 had mild cognitive impairment, and 327 had AD dementia. The NfL level was increased at baseline in patients with mild cognitive impairment and AD dementia (mean levels: cognitive unimpairment, 32.1 ng/L; mild cognitive impairment, 37.9 ng/L; and AD dementia, 45.9 ng/L; P < .001) and increased in all diagnostic groups, with the greatest increase in patients with AD dementia. A longitudinal increase in NfL level correlated with baseline CSF biomarkers (low Aβ42 [P = .001], high total tau [P = .02], and high phosphorylated tau levels [P = .02]), magnetic resonance imaging measures (small hippocampal volumes [P < .001], thin regional cortices [P = .009], and large ventricular volumes [P = .002]), low fluorodeoxyglucose-positron emission tomography uptake (P = .01), and poor cognitive performance (P < .001) for a global cognitive score. With use of the ATN system, increased baseline NfL levels were seen in A-T+N+ (P < .001), A+T-N+ (P < .001), and A+T+N+ (P < .001), and increased rates of NfL levels were seen in A-T+N- (P = .009), A-T+N+ (P = .02), A+T-N+ (P = .04), and A+T+N+ (P = .002). Faster increase in NfL levels correlated with faster increase in CSF biomarkers of neuronal injury, faster rates of atrophy and hypometabolism, and faster worsening in global cognition (all P < .05 in patients with mild cognitive impairment; associations differed slightly in cognitively unimpaired controls and patients with AD dementia). CONCLUSIONS AND RELEVANCE: The findings suggest that plasma NfL can be used as a noninvasive biomarker associated with neurodegeneration in patients with AD and may be useful to monitor effects in trials of disease-modifying drugs.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Mattsson N, Cullen NC, Andreasson U, et al. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol. 2019. PMID: 31009028. doi:10.1001/jamaneurol.2019.0765

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。